. The Problem of Recruitment for Clinical Trials
Clinical trials provide the primary method for evaluating the efficacy and safety of new therapeutic agents and procedures. The details of the study design, entry criteria, toxicities, and monitoring procedures are described in a protocol document. Clinical investigators recruit a target number of patients into a clinical trial, in which the patients receive one or more therapeutic interventions. At the end of the trial, the investigators evaluate the interventions by comparing the observed outcomes for patients receiving these therapies. Because the relative advantage of one therapeutic intervention compared with another may be small, some clinical trials require large sample sizes in order to have sufficient power to detect statistically significant differences between treatment arms. Failure to recruit a sufficient number of participants within a defined time frame may jeopardize the successful completion of a clinical trial. For example, because of insufficient recruitment, none of the 10 clinical trials monitored by one division of the Veterans Administration could be completed on time, and two of these trials had to be terminated prematurely [1] . Other studies have reported similar discouraging results [2, 3] .
1. HIV positive or diagnosed with AIDS 2. Platelet count greater than 75,000/mm 3 3. CD4 count less than 300/mm 3 4. SGOT less than two times upper limit of normal 5. Cerebrospinal fluid tested negative for cryptococcus 6. Age greater than 18 years 7. No therapy with rifampin, phenytoin carbamazepine, phenobarbital, or cortico-steroids within last 30 days 8. No prior therapy with AZT for longer than 90 days that required a daily dose of 1200 mg/day or more Figure 1 Examples of eligibility criteria for clinical trials. The criteria typically require that a patient has certain diagnosis (e.g., AIDS), that selected laboratory-results be in certain ranges (e.g., upper limit on CD4 count), and that the patients be in certain demographic categories (e.g., age group). Sometimes expensive or invasive tests need to be performed (e.g., obtaining cerebrospinal fluid). Some criteria may be subject to the physician's control (e.g., medication restrictions).
Recruitment of patients into a clinical trial entails examining their medical records, and matching their characteristics to specified eligibility criteria. These criteria include demographic characteristics, prior or current diagnoses, laboratory-test results, subjective symptoms, physical findings, current or prior medications, and drug allergies ( Figure 1 ). We developed a model of how a clinician identifies patients who are eligible for a clinical trial ( Figure 2 ). For patients who satisfy the basic eligibility requirements (e.g., a diagnosis of AIDS), and whose routine laboratory-test results (i.e., those results commonly obtained in the course of routine health care) fall within the range specified by the clinical-trial protocol (e.g., platelet count greater than 75,000/mm 3) , a clinician may collect additional information and adjust a patient's treatment therapies to render the patient eligible. Thus, the clinician may order unusual tests specifically required by the clinicaltrial protocol (e.g., lumbar-puncture studies), and she may evaluate subjective factors, such as the likelihood of patient compliance with the requirements of the protocol. Finally, she may make the necessary adjustments (e.g., changing the prescribed medications) to render patients eligible for the clinical trial. Confirmation of eligibility may require more than one evaluation, during which a patient's condition may change. Thus, identifying an eligible participant for a clinical trial is a dynamic and time-consuming process. The number and complexity of the eligibility criteria for these protocols mean that potentially eligible patients may be overlooked. Compounding the intricacy of the eligibility-determination process is the fact that, in a large academic clinic, dozens of clinical trials may be active simultaneously. Thus, it is not surprising that our preliminary effort to explore clinician's screening process suggested that potentially eligible patients were overlooked during the cause of clinical practice [4] . Figure 2 The process of identifying a patient who is eligible for a clinical trial. For patients who satisfy the basic eligibility requirements, and whose routine laboratory-test results fall within the range specified by the clinicaltrial protocol, a clinician may collect additional information and adjust a patient's clinical characteristics to render the patient eligible. A clinician may elect to re-evaluate a patient at a later time if she thinks the patient's condition may be changing.
Given this model of how a clinician evaluates patient eligibility for a clinical trial, a computer program can assist the clinician by identifying areas of incomplete information, by indicating the possibility of a patient's condition changing, and by identifying characteristics that can be modified or acted on to render a patient eligible. By automating part of the eligibility-determination process, a decision-support system can reduce the information load placed on the clinician and allow the clinician to be more systematic in identifying potentially eligible patients. In Section 2, we describe a methodology for developing such a system. We applied the methodology to screen retrospectively a sample of HIV-positive patients for the HIV and AIDS clinical trials that were active at the countyoperated hospital where the patients were receiving care. Our results (Section 3) suggest that an automated eligibility-determination program such as ours has the potential to increase a clinical trial's accrual rate. Finally (Section 4), we discuss our method of determining eligibility in the context of the recruitment strategies that have been proposed in the literature, and explore the possible applicability of our method for determining whether practice guidelines apply in particular clinical situations.
A Methodology for Automated Eligibility Determination
To develop a program that assists clinicians determining patients' eligibility for clinical trials, we first designed a computer-interpretable language for expressing eligibility criteria (Section 2.1). We developed a classification of eligibility criteria to characterize eligibility criteria in terms of the objectiveness, variability, and controllability of the underlying clinical conditions (Section 2.2). We define the eligibility score of each patient visit with respect to a specific eligibility criterion, and then combine these scores for any protocol to derive a summary eligibility status that represents a patient's eligibility for that protocol on that visit.
On a particular visit, often there are insufficient data to establish unambiguously the patient's eligibility. In the absence of current data, a clinician can infer the probability that a patient will satisfy a given criterion based on her knowledge of past data, related conditions, and statistics of typical clinical scenarios in relevant patient groups. Thus, an approach for computing and summarizing eligibility scores must define the eligibility scores as measures indicating the degree to which the patient satisfies the criterion on that visit, and, in the absence of key data, must use knowledge about past and related data to compute a patient's eligibility score . We developed two approaches for defining the scores, and for combining the scores into a summary eligibility status. The first approach defines a qualitative score to represent the likelihood that a patient satisfies an eligibility criterion. It uses heuristic assumptions about missing data to assign the scores, and a multivalued propositional logic to summarize the eligibility status of a patient (Section 2.3). The second approach defines the eligibility score as the subjective probability that the patient satisfies an eligibility criterion. It uses a Bayesian belief network to update the probabilities that a patient satisfies eligibility criteria for which no direct observation is available, and to derive the probability that a patient satisfies all eligibility criteria of a clinical trial protocol (Section 2.4). We compare and contrast the two approaches (Section 2.5), and propose a synthesis that combines the strengths of both approaches (Section 2.6)
. 1 . Description of Eligibility Criteria
We developed a simple language for expressing the eligibility criteria of clinical-trial protocols. In this language, we define time-stamped parameter values (such as the value of a patient's platelet count) and interval-based events (such as the duration of zidovudine administration). Each type of eligibility criterion has associated templates for translating a particular criterion into database queries. These database queries check to see whether the condition expressed by an eligibility criterion holds for a patient at a particular time within a protocol-defined window of acceptability of the data. Any data within the window of acceptability are treated as though they were data for the current visit. For example, a clinical-trial protocol that assesses the efficacy of the drug itraconazole for HIV-infected patients who have urinary cryptococcosis may require laboratory tests be completed within two weeks before protocol entry. Thus, a test result is considered missing only if no value is available during the two weeks prior to the visit for which we are determining protocol eligibility.
. . Classification of Eligibility Criteria
A protocol may require that eligible patients must have a specific entry diagnosis (e.g., AIDS). Other criteria may require relatively subjective assessment of the patients (e.g., compliance, willingness, and estimated survival). Some criteria, such as exclusions based on prohibited medications, depend on conditions over which physicians have a degree of control. So that our program would be sensitive to the variability and controllability of patient conditions, we organized the criteria into five groups: (1) stable requisite, (2) variable routine, (3) controllable, (4) subjective, and (5) special.
The stable-requisite criteria are preconditions that are immutable; that is, they are conditions that persist unchanged-such as having a history of a disease, having intolerance to certain drugs, or having received a prior treatment.
The variable-routine criteria are criteria that depend on data that are relatively stable over short periods, such as the results of laboratory tests, and that are collected routinely during patient care. Laboratory studies for HIV-positive patients that would be classified as variable-routine criteria include CD4 count, white-blood-cell (WBC) count, and platelet count.
The controllable criteria involve patient circumstances that a physician can modify. For example, a protocol may specify that a particular drug should not be administered within 30 days before enrollment. By substituting a similar drug and by waiting 30 days, the physician can change the patient status from ineligible to eligible.
The subjective criteria involve a physician's judgment. Examples of such criteria are estimates of the likelihood that a patient will comply with the requirements of the protocol, the likely duration of patient survival, and the Karnofsky score that summarizes a patient's functional capacity.
Finally, the special criteria are those criteria that depend on results of unusual laboratory tests that are not typically performed in the context of everyday care. These laboratory tests, such as lumbar-puncture studies and urinary excretion of heavy metal, may be costly or invasive. They are usually performed after a patient is identified as a likely study candidate.
This classification of eligibility criteria serves two purposes. Prospectively, our program can recognize a patient who has failed to satisfy only variable or controllable eligibility criteria, and can then alert the clinician to the possibility that the patient may become eligible later or if specific actions are taken. Retrospectively, the classification allows us to analyze the reasons for which a patient or a group of patients fails to satisfy the eligibility requirements of clinical trials.
. 3 . Qualitative Approach to Computing and Summarizing Eligibility
Once we have represented the eligibility criteria from each protocol and have classified those criteria within one of our five groups, it is necessary to compute and summarize the eligibility scores of patients with respect to these criteria. The qualitative approach for computing and summarizing the eligibility status defines discrete, nonnumeric eligibility scores to represent our estimate of whether the patient satisfies a given criterion on a given visit. It uses missing-value assumptions to assign eligibility scores in the absence of current data, and it relies on a multivalued propositional logic to derive summary eligibility scores.
For a given patient visit and a given protocol eligibility criterion, the qualitative scores for eligibility are defined as follows:
The patient meets the criterion on this visit; the only assumption made, if any is required, is a safe default assumption.
PP: The patient probably meets the criterion on this visit; only a reasonable assumption is made about the missing datum.
N: The datum that we need to determine whether the patient meets the criterion on this visit is not available; no reasonable assumption can be made about it.
FP: The patient probably fails to meet the criterion on this visit, based on a reasonable assumption about the missing datum.
F: The patient fails to meet the criterion on this visit; the only assumption made, if any is required, is a safe default assumption.
In all cases, if current data exist, the current data determine the eligibility score. In situations where there are no current data, we apply parameter-specific (and possibly protocol-specific) missing-data assumptions to assign eligibility scores. For each parameter, we attach two assumptions, one for the case where there is a previous datum, and one for the case where there is none. To prevent overlooking patients who may be eligible, we designed these assumptions specifically to be inclusive, rather than exclusive. A list of the assumptions that are attached to parameters follows.
• Default: Assume the default value, and if the default value satisfies the criterion, then assign score P; otherwise, assign score F (e.g., if the medical record does not mention that a patient is enrolled in a clinical-trial protocol, it is safe to assume that the patient is not enrolled).
• Immutable: Use the previous value, and if the previous parameter value satisfies the criterion, then assign score P; otherwise, assign score F (e.g., the gender of the patient being male). • Stable satisfied: If the previous parameter value satisfies the criterion within a given time period, then assign score PP; otherwise, assign score N (e.g., platelet count within the necessary range two days ago).
• Assume satisfied: If there is no previous datum, then assume that the criterion is satisfied and assign score PP (e.g., assume that patient does not have seizure disorder).
• No assumption: If the datum is missing, make no assumption and assign score N (e.g., the value of a laboratory-test result such as platelet count).
• Complex : Use as the assumption for the parameter a complex rule, possibly involving data concerning related parameter (e.g., when no current measurement of CD4 count is available, whether the presumed value falls within a given range depends on the level of the previously measured value). Figure 3 illustrates the application of the missing-value assumptions. We assume that patient problems have not occurred if they are not recorded explicitly in the medical record. Because of this assumption, although the patient in Figure 3 was known to be seropositive, it was assumed that he did not have AIDS until a diagnosis of AIDS was recorded on August 19, 1990. Once the diagnosis of AIDS was established in the record on August 19, the patient satisfied both the HIV-positive and AIDS criteria on and after that date. For certain laboratory-test results, such as a hematocrit or platelet count, we assume that the patient satisfies the criteria if he satisfies the criteria within a specific time period. No assumption is made if there were no previous laboratory data. Note that the assignment of eligibility score in this qualitative approach is sensitive to the missing-value assumptions. If, in the absence of current data, we make more liberal assumptions regarding the likelihood that patients satisfy an eligibility criterion, the program will conclude that more patients are likely to be eligible at a given time. Thus, by making alternative missing-value assumptions, we can make the program more or less inclusive in its search for potentially eligible patients.
Determining the desired inclusiveness in the search for potentially eligible subjects requires sensitivity-versus-specificity tradeoffs. If we make the program more inclusive, then the program is more sensitive (i.e., more truly eligible cases-the true positives-are identified), but is less specific (i.e., more ineligible cases-the false positives-are included). On the other hand, making the program less inclusive makes it less sensitive, but more specific. This sensitivity-versus-specificity tradeoff also makes different demands in terms of the time and work required of clinicians. Having more cases in the potentially eligible pool theoretically allows higher rates of enrollment, at the cost of additional time spent contacting potentially eligible patients and confirming eligibility.
For a given protocol and clinic visit, once the individual criterion scores for a patient have been established, we combine the scores to obtain a summary eligibility status of that visit for that protocol. In the qualitative approach, we define a simple multivalued propositional logic to summarize the eligibility scores.
Let {P j }, the set of eligibility criteria for protocol P, be the set of proposition symbols. A sentence in this logic is defined recursively as follows:
1. For all j, Pj is a sentence, 2. If S 1 and S 2 are sentences, then so are (S 1 AND S 2 ) and (S 1 OR S 2 ).
Establishing the eligibility scores of a patient visit with respect to the eligibility criteria of a protocol is precisely equivalent to giving an interpretation to the propositional symbols of this logic. An interpretation of a propositional logic is an assignment of a truth value to the propositional symbols. In this logic, the truth values are the possible eligibility scores P, PP, N, FP, and F. For any sentence S, an interpretation I is said to be an interpretation for S if I assigns a truth value to each of the propositional symbols of S. Let us denote the truth value of a sentence S under interpretation I as E(S, I). We can determine the truth value of a sentence S by applying the following semantic rules:
1. If S is a single propositional symbol, then the truth value of S is the one assigned to S by the interpretation I, 2. If S is a conjunction (S 1 AND S 2) , then the truth value of S is (E (S 1 , I ) AND E (S 2 , I) ), where the truth value of (E (S 1 , I ) AND E(S 2 , I)) is defined by Table 1 , 3. If S is a disjunction (S 1 OR S 2) , then the truth value of S is (E (S 1 , I ) OR E (S 2 , I) ),
where the truth value of (E (S 1 , I ) OR E(S 2 , I)) is defined by Table 2 . Table 2 OR truth table for combining eligibility scores. Table 1 and Table 2 define the semantics of the eligibility score categories. The Tables determine the eligibility score of a patient with respect to a compound criterion such as (((HIV status = positive) OR (AIDS status = positive)) AND (platelets > 75,000/mm3)). For example, on August 12, 1990 , the patient case in Figure 4 had the eligibility score of P with respect to the HIV-positive criterion, the eligibility score of F with respect to the AIDS criterion, and the eligibility score of PP with respect to the platelet-count criterion. By applying the OR Table to the P and F eligibility scores, we determine that the eligibility score of that patient with respect to the compound criterion ((HIV status = positive) OR (AIDS status = positive)) was P. Similarly, by applying the AND Table to combine the P and PP eligibility scores, we conclude that, on August 12, 1990 , the patient's eligibility score with respect to the overall eligibility criterion, (((HIV status = positive) OR (AIDS status = positive)) AND (platelets > 75,000/mm3)), was PP ( Figure 4 ). Figure 4 Example of using the AND and OR truth tables to derive a summary eligibility status for a patient visit. On August 12, 1990 , the patient has a summary eligibility status of PP calculated by repeated applications of the AND and OR truth tables (Tables 1 and 2, respectively) . Thus, the patient is provisionally eligible based on the missing-data assumption that his platelet count from July 29, 1990 remained within the specified range on August 12, 1990.
Given an assignment of eligibility scores to individual eligibility criteria, Tables 1 and 2 allow us to derive the eligibility score of arbitrary combinations of criteria. The entire set of eligibility criteria of a clinical-trial protocol is one such combination. We can similarly express the eligibility-criteria classes that we have defined. Thus, if the criteria on HIV and AIDS status in the previous example are stable-requisite criteria, and if the criterion on platelet count is a variable-routine criterion, then we can write a sentence S A expressing the stable-requisite criteria of the protocol as "(HIV status = positive) OR (AIDS status = positive)," and a sentence S b expressing the variable-routine criteria as "(Platelets > 75000/mm 3) ." The eligibility criteria of the protocol as a whole could then be written as a conjunction of the stable-requisite and variable-routine criteria: (S A AND S B ). Using the truth tables, we can establish the truth values of S A and S B , and hence the eligibility scores of the patient with respect to these classes of criteria. As a result, we can make a summary statement, such as "On this visit, the patient failed to meet the eligibility requirements of this protocol; she had PP score on the stable-requisite criteria, but F score on the variable-routine criteria," meaning that the patient was not eligible on this visit because some of her laboratory-test results failed to meet protocol requirements, although she had the right demographic and disease profiles. Because laboratory-test results vary over time, this patient could potentially satisfy the eligibility criteria at a later visit.
. 4 . Probabilistic Approach to Computing and Summarizing Eligibility
The qualitative missing-value assumptions discussed in Section 2.3 represent (1) prior belief in the likelihood that a patient satisfies an eligibility criterion in the absence of current data, and (2) dependencies among the past and present values of parameters. This insight has led us to formulate a probabilistic approach to computing and summarizing eligibility status. This approach uses a Bayesian belief network to represent the eligibility criteria of a clinical-trial protocol and dependencies among data values.
A Bayesian belief network is a directed acyclic graph in which the nodes represent random variables and the links represent dependencies ( Figure 5 ). The dependencies can be probabilistic or deterministic. The joint distribution of all the random variables in the network is a unique product of the individual distributions for each random variable [5] . Thus, the product of the distributions is guaranteed to have no unspecified parameters and to contain no conflict. As a consequence, if we wish to have a complete and consistent set of missing-value assumptions, it is sufficient to assess the distributions for the nodes in the network.
In the probabilistic approach, the eligibility score of a patient with respect to a criterion at a particular time is defined as the probability that the patient satisfies that criterion. If current data are available, the probability is either 0 or 1; otherwise, the eligibility status is expressed as a probability between 0 and 1.
There are three types of nodes in a Bayesian network representation of the eligibility criteria. The first type of node, such as the nodes labeled HIV+, AIDS, and Platelets>75K in Figure 5 , represents the proposition that a patient satisfies the individual eligibility criteria of the protocol. The second type of node, such as the nodes labeled Eligible and Diagnosis, represents the proposition that a patient satisfies a combination of criteria joined by AND and OR connectives. The third type of node, such as the nodes labeled Normal WBC and Platelets>75K previously, represents propositions whose truth values affect the probability that a patient satisfies the eligibility-criteria nodes. The links between the nodes may be deterministic or probabilistic. The links between nodes that represent an AND or OR combination of criteria and these nodes' predecessors are deterministic links. Such links have degenerate conditional distributions. The probabilistic links-such as those between current platelet count, the WBC count, and previous platelet count-represent uncertain relationships. For example, given that the current white-blood-cell count is normal and the platelet count was greater than 75,000/mm 3 a month ago, the current platelet count is still likely to be greater than 75,000/mm 3 ( Figure 5 ).
The basic computation on Bayesian belief networks is the computation of every node's posterior probability given the evidences that have been observed. There are well-known algorithms for computing such probabilities [6] . In the case of computing the eligibility status of the patient with respect to a clinical trial, we use observed patient data to determine the probability (0 or 1) associated with the nodes in the Bayesian network (e.g., current WBC value is normal and the patient is known to be HIV positive), and we update the posterior probabilities of other nodes for which we have no direct observation (e.g., platelet count greater than 75,000/mm 3 ). Because the conjunction and disjunction of the eligibility criteria are represented as explicit nodes in the network, computing the posterior probability gives us the probability that the patient satisfies all the eligibility criteria of a clinical-trial protocol, given the available data. In addition, we obtain the probabilities that the patient satisfies aggregate criteria, such as the stable-requisite, variable-routine, controllable, subjective, and special criteria.
Comparison of Qualitative and Probabilistic Approaches
Both the qualitative and probabilistic approaches of computing and summarizing eligibility status represent the eligibility criteria, define eligibility scores, deal with the problem of missing data, and provide ways of summarizing the eligibility score. At the level of indicating whether available data support the proposition that the patient satisfies a particular criterion, there is a close parallel between the qualitative and the probabilistic approaches. Where the qualitative approach assigns a nonnumeric score (e.g., PP, N, or FP), the probabilistic approach uses a numeric probability between 0 and 1 to represent the same measure. Given the classification of eligibility criteria into the five groups as described in Section 2.2, both qualitative and probabilistic approaches can identify patients who may become eligible if laboratory-test values change or if a clinician takes actions to eliminate clinician-controllable exclusions.
The two approaches diverge significantly in their representation of missing-value assumptions and in their methods of summarizing the overall eligibility status. The qualitative approach represents the missing-value assumptions as a set of heuristic rules. Because these rules can be arbitrarily complex, there is no automated method to verify their consistency and completeness. 1 The probabilistic approach uses prior distributions to represent the likelihood that a typical patient would meet an eligibility criterion, and conditional distributions to represent how related parameters and past patient states affect our belief about the current patient state.
The summary scores generated by the two approaches have different meanings. The probabilistic approach computes the probability that a patient satisfies all eligibility criteria. In contrast, the summary score computed in the qualitative approach does not have a probabilistic interpretation. For example, in the qualitative approach, if a patient's overall eligibility status is PP for a clinical trial, the system is not saying that the patient probably satisfies all the eligibility criteria of that clinical trial. Instead, the score PP indicates that the patient probably satisfies (having a PP score) at least one eligibility criterion, and satisfies (having a P score) the remaining criteria. A simple example illustrates the distinction: A patient who has probability 0.9 of satisfying each of 10 independent eligibility criteria has probability 0.35 of satisfying all the criteria simultaneously. In the qualitative approach, the summary score of the patient for the 10 criteria will be PP, yet the probability of that patient satisfying all criteria is low.
The overall probability computed in the probabilistic approach makes a stronger statement about a patient's eligibility than that made by the summary status computed in the qualitative approach. The qualitative summary focuses attention on the lowest eligibility score of a patient with respect to each criterion in a conjunction of criteria. If a patient does not fail any criterion, but there is reason to believe that he probably fails one criterion (i.e., there is no F score, but there is at least one FP score), then the qualitative approach assigns an overall score indicating that the patient provisionally fails to satisfy the set of criteria (i.e., FP score for the set of criteria). The probabilistic approach can simulate the qualitative summary score by computing the minimum of the probabilities that a patient satisfies the individual criteria in a conjunctive set of criteria, and the maximum of the probabilities that a patient satisfies the individual criteria in a disjunctive set of criteria. For example, if the probability that a patient satisfies an eligibility criterion is 0.2 (analogous to an FP score), while he satisfies each of the remaining criteria with probability of 0.5 (analogous to an N score), taking the minimum of the probabilities gives us 0.2 (analogous to an FP score). Thus, the probabilistic approach can duplicate the summary scores of the qualitative approach. In addition, the probabilistic approach can compute the probability that a patient satisfies all eligibility criteria.
The ability to make a stronger statement about the patient's probability of satisfying all eligibility criteria of a clinical trial comes at a price. First, the dependencies among all the criteria of the clinical trial must be modeled, which, for a clinical trial with dozens of eligibility criteria, is nontrivial. For example, a patient with a high Karnofsky score is more likely to have normal renal and liver function. Taken separately, "high Karnofsky = true" and "normal liver function = true" may both have probability of 0.9, but the conditional probability of having normal liver function given a high Karnofsky score is greater than 0.9. Thus, in this example, the probability of having both a high Karnofsky score and normal liver function is greater than 0.81, the probability of the joint event if the two conditions are independent of each other. Second, constructing a good Bayesian belief network requires an assessment of the necessary prior distributions on those nodes with no predecessors as well as the conditional distributions on the nodes with predecessors. While it is possible to obtain the necessary distributions from data sets in a few cases, the distributions have to be elicited from domain experts in most cases. Finally, exact probabilistic inference in a general belief network has been shown to be NP-hard [7] , whereas using truth tables to combine the qualitative scores is linear in the number of criteria.
. 6 . A Combined Approach
The complementary strengths and weaknesses of the qualitative and probabilistic approaches suggest the value of a combined approach that draws on the strengths of each. The strength of the probabilistic approach lies in its management of uncertainty whereas the qualitative approach has a simple summarization procedure. In the combined approach, we use the Bayesian belief-network formalism to represent individual eligibility criteria and the missing-value assumptions. For nodes for which we have current data, we query the database to determine exactly whether a patient satisfies those criteria, and use a beliefnetwork inference algorithm to update the probabilities that a patient satisfies those criteria for which no data are available. Once we have established the likelihood that a patient satisfies each eligibility criterion for a clinical trial, we map the probabilities into qualitative scores. Using the AND and OR truth tables, we then derive summary scores, as in the qualitative approach ( Figure 6 ). This combined approach allows uniform and consistent representation of the missing-value assumptions, and a principled way of computing beliefs regarding the probability that a patient satisfies each eligibility criterion at a given time. By converting the probabilities to qualitative scores and using the AND and OR truth tables to combine the scores, the combined approach avoids the need to make any assumptions of dependency among the eligibility criteria of a clinical trial. The resulting summary score still has clear semantics as defined by the truth tables, even though no statement about the precise likelihood that a patient satisfies all the eligibility criteria at a given time can be made.
Results
In the THERAPY-HELPER system [8] , we implemented the qualitative approach to determining patients' eligibility for clinical trials. The eligibility criteria were encoded for the 17 HIV and AIDS protocols that were active at Santa Clara Valley Medical Center (SCVMC) in 1990. Given a protocol identifier, a patient identifier, and a visit date, the computer system uses patient data stored in a relational database to determine the eligibility status of the patient on a per-protocol per-visit basis. We used the system to analyze retrospectively the eligible status of a sample of patients during a 7 month period.
We randomly selected, from a pool of HIV-infected patients seen at SCVMC between January 2, 1990 and August 5, 1990, 60 patients who were HIV-positive, 30 of whom did not yet have a diagnosis of AIDS. The medical records for these 60 patients were abstracted and the information needed for determining eligibility were entered into a relational database. The 60 patient cases had a total of 301 patient visits during the sample period.
For each protocol, we classified the patient cases as follows:
• Provisionally eligible: Patient cases that had at least one visit that was assigned a summary score of P or PP,
• Potentially eligible: Patient cases that had no visit that was assigned a summary score of P or PP, but had at least one visit that was assigned an N score, • Not eligible: Patient cases that had no visit that was assigned a summary score of P, PP, or N, but had at least one visit that was assigned an F or FP score.
The results of our analysis indicate that clinicians inadvertently missed a significant number of opportunities for enrolling patients in clinical trials. Twelve of the 60 patients (20 %) were provisionally eligible for at least one protocol during the sample period, but were not enrolled. Four of these 12 patients were each provisionally eligible for two protocols. Fifty-four of the 60 patients (90 %) could not be ruled out as ineligible for clinical trials, and ten (17 %) satisfied all except controllable criteria. Moreover, data required for eligibility evaluation were frequently missing: platelet counts were missing for a mean of 92 visits (31%); CD4 counts were missing for a mean of 128 visits (43%). While it is possible that some of the provisionally eligible patients were recognized to be eligible, but refused to participate in the clinical trials for other reasons, the amount of missing information suggests that an automated eligibility screening program could increase patient accrual by alerting clinic staff to those data that should be collected and to those criteria that can be manipulated.
Discussion
Two classes of recruitment strategy have been used to enroll participants in clinical trials: mass screening, in which the research team uses sources such as mass mailings to identify and screen potential participants, and referral, in which the team relies on cooperating clinicians (who may be members of the research team) to refer or enroll eligible participants [9] . The technique of mass screening identifies contacts in a population pool, subjects them to a screening evaluation, and then asks them to return for a number of protocol screening visits to ensure that they meet the eligibility criteria. At each point in the evaluation process, the research team uses eligibility criteria to filter a pool of potential participants until only eligible subjects are left in the pool. In the referral strategy, a clinician may observe for a period of time a pool of patients who are receiving care in the clinic. When she identifies a potentially eligible patient, she may request a series of special tests to confirm or disprove eligibility.
The eligibility-determination methodology described in this paper can be adapted to both the mass-screening and referral strategies of patient recruitment. Given a database of patient information, at each point in the mass-screening process, the program can identify those patients who have not failed to meet any eligibility criteria. As more data about the patients are collected, the program can refine the list of patients who remain potentially eligible. In the referral approach, a program based on our methodology can assist a clinician in the decision-making process by classifying eligibility criteria and by computing eligibility scores for individual criteria as well as for these classes of criteria. Thus, the program can identify patients whose failure to satisfy the eligibility criteria is based on changeable or physician-controllable parameters or on missing data.
Relatively few computer-based systems for matching patients with clinical trials have been described in the literature. Some systems, such as HIV ProtoCall used at Beth Israel Hospital in Boston [10] , display information on eligibility criteria for a clinician who is trying to decide whether her patient could enter a particular clinical trial. Those systems, however, do not actively match the patient characteristics to the requirements of the protocol. Projects that automate matching of patients to clinical trials, such as Trial Search developed at Davis Medical Center in San Francisco [11] , evaluate a patient's eligibility at a point in time, but do not provide support in an ongoing evaluation process where patient conditions may change, additional tests may be ordered, and clinicians may intervene to render a patient eligible.
The application of computer technology to the problem of matching patients with the clinical trials for which those patients are eligible holds great promise. Unlike diagnostic programs that require extensive knowledge about diseases and their possible signs and symptoms, the domain knowledge required by eligibility-determination systems is constrained by the eligibility criteria of clinical-trial protocols. Even with relatively simple missing-value assumptions, the THERAPY-HELPER system was able to identify a number of patients who were potentially eligible for clinical trials, but who had not been evaluated by their physicians for possible enrollment into these trials.
The methodology for finding eligible patients for clinical trials has applicability beyond clinical research. In many respects, clinical-trial protocols are similar to medical practice guidelines whose importance and potential influence are receiving increasing recognition. A medical-practice guideline is a set of standardized specifications for care developed by a formal process that incorporates the best scientific evidence of effectiveness with expert opinion [12] . A good practice guideline clearly defines the indications for both appropriate and inappropriate tests and procedures. These criteria of appropriateness incorporate all clinical and laboratory factors that are relevant to the choice of intervention, just as the eligibility criteria of a clinical-trial protocol define those conditions that a patient must satisfy before receiving care under the protocol. A clinician deciding to use a practice guideline to treat a patient faces problems similar to those that she encounters in enrolling a patient in a clinical trial: current data may not be available for key criteria, and the patient may fail only criteria based on changeable or physician-controllable parameters. Thus, the methodology described in this paper can also be applied to the problem of determining whether practice guidelines are applicable in a given clinical situation.
